Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options

2020/06/15 by Wolfgang Löscher, Heidrun Potschka, Sanjay M. Sisodiya +1 · 876 citations
Medicine · Neuroscience · Psychology · #Biology #Drug Resistant Epilepsy #Drug resistance #Ecology #Epilepsy #Epilepsy research and treatment #Genetics #Intensive care medicine #Medicine #Neuroscience #Neuroscience and Neuropharmacology Research #Pharmacological Effects and Toxicity Studies #Pharmacology #Psychiatry #Psychology #Resistance (ecology)

paper · pdf · doi:10.1124/pr.120.019539

published in Pharmacological Reviews 72(3), 606-638 (American Society for Pharmacology and Experimental Therapeutics)

openalex publication_date 2020/06/15 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Citations

• Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies
• Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors
• The epidemiology of drug‐resistant epilepsy: A systematic review and meta‐analysis

Cited by

• Connectome-wide mega-analysis identifies a reproducible functional network signature of temporal lobe epilepsy
• The human photosensitive epilepsy model for clinical proof‐of‐principle trials of novel antiseizure medications: 2. Analysis of drug trials and predictive value of the model
• Diagnostic performance of neuroimaging modalities for epileptogenic focus localization: A systematic review
• Pyroptosis in neurodegenerative diseases: from bench to bedside
• Neuroinflammatory mediators in acquired epilepsy: an update
• The Influence of the Probiotics, Ketogenic Diets, and Gut Microbiota on Epilepsy and Epileptic Models: A Comprehensive Review
• GABA-dependent microglial elimination of inhibitory synapses underlies neuronal hyperexcitability in epilepsy
• Seizures beget more than seizures: Understanding the cellular, structural, individual and societal impact of seizures in epilepsy
• Real‐world use of cenobamate in pediatric focal epilepsies and developmental epileptic encephalopathies: A multicenter retrospective series
• Redefining drug‐resistant epilepsy: Insights from an Italian Delphi consensus study
• Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine
• Deficiency of nNOS in adult‐born dentate granule cells causes epilepsy
• Real‐world effectiveness and tolerability of cenobamate in drug‐resistant epilepsy: A retrospective analysis of the patients included into the Early Access Programs (EAP) in Germany, France, and United Kingdom
• Voluntary running wheel activity reduces seizure burden and affords neuroprotection in a mouse model of acquired epilepsy
• Population pharmacokinetics of levetiracetam in patients diagnosed with refractory epilepsy: A real‐world study
• One‐hertz low‐frequency stimulation of anterior substantia nigra pars reticulata attenuates seizure via biased disinhibitory circuits
• Closed-loop control of seizure activity via real-time seizure forecasting by reservoir neuromorphic computing
• The efficacy and safety of ketogenic diet therapy among adolescents and adults with drug resistant epilepsy: A systematic review and meta-analysis
• Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies. [europepmc]
• Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. [europepmc]
• Mechanisms of Drug Resistance in the Pathogenesis of Epilepsy: Role of Neuroinflammation. A Literature Review. [europepmc]
• The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. [europepmc]
• Neuroinflammation: A Signature or a Cause of Epilepsy? [europepmc]
• The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies. [europepmc]
• Elucidating the Potential Side Effects of Current Anti-Seizure Drugs for Epilepsy. [europepmc]
• Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development. [europepmc]
• Reprogramming reactive glia into interneurons reduces chronic seizure activity in a mouse model of mesial temporal lobe epilepsy. [europepmc]
• Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice. [europepmc]
• Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives. [europepmc]
• Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. [europepmc]
• Animal Models of Epilepsy: A Phenotype-oriented Review. [europepmc]
• The Quality of Life of Children with Epilepsy and the Impact of the Disease on the Family Functioning. [europepmc]
• TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model. [europepmc]
• The role of Na + -K + -ATPase in the epileptic brain. [europepmc]
• Dogs as a Natural Animal Model of Epilepsy. [europepmc]
• Discrete subicular circuits control generalization of hippocampal seizures. [europepmc]
• Astrocytes in the initiation and progression of epilepsy. [europepmc]
• Neuroinflammatory mediators in acquired epilepsy: an update. [europepmc]
• Animal Models of Drug-Resistant Epilepsy as Tools for Deciphering the Cellular and Molecular Mechanisms of Pharmacoresistance and Discovering More Effective Treatments. [europepmc]
• Oxidative Stress and Neurodegeneration in Animal Models of Seizures and Epilepsy. [europepmc]
• Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders. [europepmc]
• A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. [europepmc]
• Insights into epileptogenesis from post-traumatic epilepsy. [europepmc]